Using Time Weighted Average Change from Baseline of SARS-CoV-2 Viral Load to Assess Impact of Hydroxychloroquine (HCQ) as Post-exposure Prophylaxis and Early Treatment for COVID-19
AUTHORS
Kumbhakar
R ,
Neradilek
M ,
Barnabas
RV ,
Stewart
J ,
Stankiewicz Karita
HC ,
Landovitz
RJ ,
Kissinger
PJ ,
Jerome
KR ,
Paasche-Orlow
MK ,
Bershteyn
A ,
Chu
HY ,
Neuzil
KM ,
Greninger
AL ,
Luk
A ,
Wald
A ,
Brown
ER ,
Johnston
C ,
. Journal of medical virology. 2022 8 8; ().
- PMID: 35940869 [PubMed].
ABSTRACT
Two randomized controlled trials demonstrated no clinical benefit of hydroxychloroquine (HCQ) for either post-exposure prophylaxis (PEP) or early treatment of SARS-CoV-2 infection. Using data from these studies, we calculated time-weighted average change from baseline SARS-CoV-2 viral load and demonstrated that HCQ did not affect viral clearance. This article is protected by copyright. All rights reserved.
Tags: alumni publications 2022